^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-DRB1*01:01

    i
    Other names: HLA-DRB1, Major Histocompatibility Complex, Class II, DR Beta 1, Major Histocompatibility Complex, Class II, DR Beta 1 Precursor, HLA Class II Histocompatibility Antigen, DR-1 Beta Chain, HLA Class II Histocompatibility Antigen, DRB1 Beta Chain, MHC Class II HLA-DR Beta 1 Chain, Human Leucocyte Antigen DRB1, Human Leukocyte Antigen DRB1, Lymphocyte Antigen DRB1, HLA-DR1B, HLA-DRB1, HLA-DRB, DRB1
    Entrez ID:
    3123
    Related biomarkers:
    Expression
    Fusion
    1year
    Design of a novel multi-epitope vaccine candidate against endometrial cancer using immunoinformatics and bioinformatics approaches. (PubMed, J Biomol Struct Dyn)
    The codon adaptation index (CAI) value and GC content of the optimised codon sequences of the vaccine were 0.986 and 54.43%, respectively, indicating that the vaccine has the potential to be highly expressed. The in silico analysis suggested that the designed vaccine may provide a novel therapeutic option for the individualised treatment of EC patients in the future.Communicated by Ramaswamy H. Sarma.
    Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • PRAME (Preferentially Expressed Antigen In Melanoma) • TMPRSS4 (Transmembrane Serine Protease 4)
    |
    HLA-A*02 • HLA-DRB1*01:01
    over1year
    A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps. (PubMed, Hum Immunol)
    CEDAR provides a comprehensive repository of epitopes related to prostate-specific antigens. This inventory of epitope data with its wealth of searchable T cell, B cell and MHC ligand information provides a useful tool for the scientific community. At the same time, we identify significant knowledge gaps that could be addressed by experimental analysis.
    Retrospective data • Review • Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    HLA-A*02 • HLA-DRB1*01:01
    3years
    HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). (PubMed, Cancer Sci)
    Eighty-two transplant-ineligible patients with newly diagnosed MM enrolled in a phase II study (JCOG1105) comparing two less intensive melphalan, prednisolone, plus Btz (MPB) regimens were subjected to HLA typing. CR was achieved in patients carrying HLA-DQB1*03:02, -DQB1*05:01, and -DRB1*01:01-class II alleles. HLA genotyping may help predict Btz-induced toxicity and treatment efficacy in patients with MM, although this needs further validation.
    Clinical • Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    HLA-DQB1*03:02 • HLA-DQB1*05:01 • HLA-DRB1*01:01
    |
    bortezomib • melphalan